LILRA4, also known as ILT7 and CD85g, is an approximately 60-70 kDa variably glycosylated transmembrane protein that regulates immune cell activation. Mature human LILRA4 consists of a 423 amino acid (aa) extracellular domain (ECD) with four immunoglobulin-like domains, a 21 aa transmembrane segment, and a 32 aa cytoplasmic domain.LILRA4 function coreceptor to limit the innate immune responses to viral infections, signaling occurs via FCER1G (PubMed:16735691, PubMed:19564354). Down-regulates the production of IFNA1, IFNA2, IFNA4, IFNB1 and TNF by plasmacytoid dendritic cells that have been exposed to influenza virus or cytidine-phosphate-guanosine (CpG) dinucleotides, indicating it functions as negative regulator of TLR7 and TLR9 signaling cascades.
95 % as determined by Tris-Bis PAGE, 95 % as determined by HPLC.
Formulierung:
Lyophilized from a 0.22 µm filtered solution of PBS, pH 7.4. Normally 8% trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Target-Kategorie:
LILRA4/CD85g
Application Verdünnung:
Lyophilized from a 0.22 µm filtered solution of PBS, pH 7.4. Normally 8% trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Anwendungsbeschreibung:
Cross-Reactivity: Centrifuge the tube before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage,it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA,5% HSA,10% FBS or 5% Trehalose),and aliquot the reconstituted protein solution to minimize free-thaw cycles. ResearchArea: Bio-Markers & CD Antigens
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
